G protein-coupled receptors (GPCRs) are expressed on the surface of cells and regulate a range of important functions. Because they are involved in so many sensory and physiological processes, ...
G-protein coupled receptors (GPCRs) are proteins triggered by ligands (protein-binding chemicals) from outside cells to ...
The discovery of G protein-coupled receptor (GPCR) heteromers has revealed a new level of complexity in their functional characteristics. This review explores a variety of methodologies and live cell ...
Opioid receptors are a subset of G protein–coupled receptors (GPCRs). These membrane proteins transmit signals into the cell ...
Up-to-date computational pipeline characterizes G-protein-coupled receptor (GPCR) repertoires in the closest relatives of metazoans, providing a framework to investigate the evolutionary origins and ...
Through an international collaboration, scientists at St. Jude Children’s Research Hospital leveraged data science, pharmacology and structural information to conduct an atomic-level investigation ...
Thought LeadersEdoardo FabiniPrincipal Scientist Evotec U.K. G-protein-coupled receptors (GPCRs) play a pivotal role in cellular signaling and have long been a major focus in drug discovery. These ...
AZoLifeSciences on MSN
Kinetic traps explain differences in GPCR drug efficacy
G-protein coupled receptors (GPCRs) are proteins triggered by ligands (protein-binding chemicals) from outside cells to transmit signals inside the cell.
One in every three FDA-approved drugs targets a single superfamily of receptors dotting the surfaces of human cells. From beta blockers to antihistamines, these essential, life-saving medications ...
Most protein-targeting drugs are prizes that drug developers have unearthed from G protein–coupled receptor (GPCR) interactomes. So, when GPCR-targeting drugs become harder to find, one might liken ...
Drug discovery can be a long and complex process. Medicines for neurodegenerative diseases like Alzheimer's disease are among the most expensive to develop, as animal model results have not proven to ...
Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic’s novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback